Figure 3From: A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideMedian platelet counts during the treatment period. Bars of line graph represent standard deviations. Broken horizontal line is at 50 × 109/L.Back to article page